Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · Aspira Pathlab & Diagnostics L · 28 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
Aspira Pathlab & Diagnostics L
BSE: 540788
BSE: 540788
Healthcare › Healthcare › Healthcare Services › Healthcare Service Provider
Aspira Pathlab & Diagnostics L
StateQ1 FY26 filed
Last close · 27 Oct 2026₹125.00
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA53.6 · 10.58 · 29.9
Aspira Pathlab & Diagnostics L is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY25–FY25 (all audited; no estimate years)
| ₹ crore · consolidated | FY25 |
|---|---|
| Revenue | 22 |
| EBITDA (ex other income) | 3 |
| margin % | 15.8 |
| Owners' profit | 0 |
| EPS, as reported (₹) | 1.97 |
| ROE % · ROCE % | 16.6 · 15.7 |
| Debt / equity (x) | 0.10 |
| Cash from operations | 2 |
| Capex | (0) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Aspira Pathlab & Diagnostics L · 28 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 5 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|
| Revenue | 5 | 6 | 5 | 6 | 5 |
| Profit before tax | (0) | 1 | 0 | 1 | 0 |
| Net profit | 0 | 1 | 0 | 1 | 0 |
| EPS (₹) | 0.10 | 0.96 | 0.30 | 0.66 | 0.41 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,676 | 45.6 | 12.46 | 36.8 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 14,858 | 79.2 | 15.52 | 41.4 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 11,403 | 23.6 | 7.48 | 27.2 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 7,875 | 28.9 | 13.44 | 28.7 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 6,272 | 64.8 | 5.62 | 24.8 | 6.9 | 8.6 | — | 25.3 |
| SURAKSHA DIAGNOSTIC LTD | 1,615 | 45.1 | 6.63 | 16.4 | 12.9 | 11.5 | — | 36.0 |
| KRSNAA DIAGNOSTICS LTD | 1,609 | 16.5 | 1.64 | 8.3 | 10.3 | 8.4 | — | 27.7 |
| 3B BLACKBIO DX LTD. | 1,199 | 20.0 | 3.61 | 14.1 | 18.1 | 22.5 | (8.9) | 52.6 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 53.6 | 23.6 | 18 of 25 | 29% |
| P/B | 10.6 | 2.1 | 21 of 24 | 13% |
| ROCE | 13.4 | 6.1 | 8 of 29 | 75% |
| ROE | 16.6 | 6.0 | 6 of 24 | 78% |
| Debt / Equity | 0.1 | 0.1 | 14 of 23 | 41% |
| EBITDA margin | 17.7 | 25.6 | 15 of 24 | 39% |
| Revenue growth | 13.2 | 20.8 | 18 of 25 | 29% |
| Profit growth | 794.9 | 22.0 | 1 of 25 | 100% |
| Market cap | 129 | 34 | 13 of 30 | 59% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · Aspira Pathlab & Diagnostics L · 28 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 8 Oct 2026 · Quarterly compliance certificate for share dematerialisation filed with BSE | compliance | minimal | — | — |
| 1 Oct 2026 · Promoter buys 245 shares of Aspira Pathlab via open market | ownership changes | high | — | — |
| 28 Sept 2026 · Promoter Jay Bhanushali buys 1,424 Aspira Pathlab shares via open market | ownership changes | low | — | — |
| 25 Sept 2026 · 53rd AGM voting results: all 5 resolutions passed | board shareholder meetings | low | — | — |
| 25 Sept 2026 · 53rd AGM held; profit plunges from INR 207L to INR 5L | board shareholder meetings | low | — | — |
| 23 Sept 2026 · Trading Window Closed from Oct 1 for H1 FY27 Results | compliance | minimal | — | — |
| 16 Sept 2026 · Promoter Jay Bhanushali acquires 1,387 shares of Aspira Pathlab via open market | ownership changes | low | — | — |
| 12 Sept 2026 · Aspira Pathlab board approves Rs 65 cr rights issue, forms committee | fund raising | medium | — | — |
| 12 Sept 2026 · Board approves Rights Issue to raise up to Rs 65 crores | fund raising | medium | — | — |
| 12 Sept 2026 · Board approves Rights Issue to raise up to Rs 65 crore | fund raising | high | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in